世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の犬の関節炎治療市場 2018-2022年

Global Canine Arthritis Treatment Market 2019-2023

IRTNTR30043

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
111

サマリー

この調査レポートは世界の犬の関節炎治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Canine Arthritis
Arthritis is the most common degenerative disease in canines. It affects the bones and joints and causes difficulties with mobility.
Technavio’s analysts forecast the Global Canine Arthritis Treatment Market to grow at a CAGR of 4.71% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the canine arthritis treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of canine arthritis across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, canine arthritis treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bayer
- Boehringer Ingelheim
- Eli Lilly
- Vetoquinol
- Zoetis
Market driver
- Growing consolidation in the industry
- For a full, detailed list, view our report

Market challenge
- Stringent drug approval process
- For a full, detailed list, view our report

Market trend
- Advent of regenerative therapies
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- NSAIDs - Market size and forecast 2018-2023
- Opioids - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer
- Boehringer Ingelheim
- Eli Lilly
- Vetoquinol
- Zoetis
PART 14: APPENDIX
- Research methodology
- List of abbreviations

-
Exhibit 01: Global animal healthcare market
Exhibit 02: Segments of global animal healthcare market
Exhibit 03: Market characteristics
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2018
Exhibit 06: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 07: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 08: Five forces analysis 2018
Exhibit 09: Five forces analysis 2023
Exhibit 10: Bargaining power of buyers
Exhibit 11: Bargaining power of suppliers
Exhibit 12: Threat of new entrants
Exhibit 13: Threat of substitutes
Exhibit 14: Threat of rivalry
Exhibit 15: Market condition - Five forces 2018
Exhibit 16: Product - Market share 2018-2023 (%)
Exhibit 17: Comparison by product
Exhibit 18: NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 19: NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 20: Opioids - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Opioids - Year-over-year growth 2019-2023 (%)
Exhibit 22: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Others - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Comparison_5
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Bayer - Vendor overview
Exhibit 44: Bayer - Business segments
Exhibit 45: Bayer - Organizational developments
Exhibit 46: Bayer - Geographic focus
Exhibit 47: Bayer - Segment focus
Exhibit 48: Bayer - Key offerings
Exhibit 49: Bayer - Key customers
Exhibit 50: Boehringer Ingelheim - Vendor overview
Exhibit 51: Boehringer Ingelheim - Business segments
Exhibit 52: Boehringer Ingelheim - Organizational developments
Exhibit 53: Boehringer Ingelheim - Geographic focus
Exhibit 54: Boehringer Ingelheim - Segment focus
Exhibit 55: Boehringer Ingelheim - Key offerings
Exhibit 56: Boehringer Ingelheim - Key customers
Exhibit 57: Eli Lilly - Vendor overview
Exhibit 58: Eli Lilly - Business segments
Exhibit 59: Eli Lilly - Organizational developments
Exhibit 60: Eli Lilly - Geographic focus
Exhibit 61: Eli Lilly - Segment focus
Exhibit 62: Eli Lilly - Key offerings
Exhibit 63: Eli Lilly - Key customers
Exhibit 64: Vetoquinol - Vendor overview
Exhibit 65: Vetoquinol - Business segments
Exhibit 66: Vetoquinol - Organizational developments
Exhibit 67: Vetoquinol - Geographic focus
Exhibit 68: Vetoquinol - Segment focus
Exhibit 69: Vetoquinol - Key offering
Exhibit 70: Vetoquinol - Key customers
Exhibit 71: Zoetis - Vendor overview
Exhibit 72: Zoetis - Business segments
Exhibit 73: Zoetis - Organizational developments
Exhibit 74: Zoetis - Geographic focus
Exhibit 75: Zoetis - Segment focus
Exhibit 76: Zoetis - Key offerings
Exhibit 77: Zoetis - Key customers

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る